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Objective To compare the use of generic and proprietary sodium stibogluconate for the treatment of visceral
leishmaniasis (kala-azar).
Methods Atotalof102patientswithconfirmedkala-azarweretreatedinamissionhospitalinWestPokotregion,
Kenya, with sodium stibogluconate (20 mg/kg/day for 30 days) — either as Pentostam
t (PSM) or generic sodium
stibogluconate (SSG); 51 patients were allocated alternately to each treatment group.
Findings There were no significant differences in baseline demographic characteristics or disease severity, or in
eventsduringtreatment.Therewere3deathsinthePSMgroupand1intheSSGgroup;2patientsdefaultedineach
group. Only1out of80 test-of-curesplenic aspirateswas positive for Leishmania spp.;this patientwas inthe SSG
group.Follow-upafter56monthsshowedthat6outof58patientshadrelapsed,5intheSSGgroupand1inthe
PSM group. No outcome variable was significantly different between the two groups.
Conclusion Theavailabilityofcheapergenericsodiumstibogluconate,subjecttorigidqualitycontrols,nowmakesit
possible for the health authorities in kala-azar endemic areas to provide treatment to many more patients in Africa.
Keywords Leishmaniasis, Visceral/drug therapy; Antimony sodium gluconate/therapeutic use; Drugs, Generic/
therapeutic use; Drug evaluation; Comparative study; Kenya (source: MeSH).
Mots cle ´sLeishmaniose visce ´rale/chimiothe ´rapie; Antimoine sodium, Gluconate/usage the ´rapeutique; Produits
ge ´ne ´riques/usage the ´rapeutique; Evaluation me ´dicament; Etude comparative; Kenya (source: INSERM).
Palabras clave Leishmaniasis visceral/quimioterapia; Gluconato de sodio antimonio/uso terape ´utico; Medica-
mentos gene ´ricos/uso terape ´utico; Evaluacio ´n de medicamentos; Estudio comparativo; Kenya (fuente: BIREME).
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Voir page 392 le re ´sume ´ en franc ¸ais. En la pa ´gina 392 figura un resumen en espan ˜ol.
Introduction
Kala-azar (visceral leishmaniasis), a debilitating
disease caused by Leishmania donovani, poses a major
health problem in East Africa, and since 1988,
Me ´decins Sans Frontie `res–Holland (MSF–H) has
treated over 45000 patients in the region with the
condition. The mainstay of this treatment remains
pentavalent antimony compounds. Since the 1940s,
Pentostam
T (PSM) (GlaxoWellcome, London, Eng-
land) (sodium stibogluconate) has been virtually the
only substance used in English-speaking East Africa
for the treatment of kala-azar and post-kala-azar
dermal leishmaniasis (PKDL). In the former French
andItaliancoloniesinAfrica,meglumineantimoniate
(Glucantime
T)( R h o ˆne-Poulenc-Rohrer, Paris) is
used. However, the high cost of PSM (see below)
makesitprohibitivelyexpensiveforbothpatientsand
the local health authorities in the affected areas.
Furthermore, usually only small amounts of PSM are
produced and the manufacturer often cannot cope
with the fluctuating high demand for the drug.
ShortfallsinsupplyhavebeenencounteredbyMSF–H
andagood-quality,butcheaper,treatmentoptionfor
kala-azar is urgently required. Generic sodium
stibogluconate B.P (SSG)) has been manufactured
by Albert David Ltd in Calcutta, India, for several
decades, and since 1997 it has been supplied by
the International Dispensary Association (IDA),
Amsterdam, Netherlands. Because of the 50-year
virtualmonopolyofPSMinEastAfricafortreatment
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induced to change to generic SSG when it has been
carefully evaluated with PSM. The content of
pentavalent and trivalent antimony in generic SSG
fallswellwithinthebatch-to-batchvariabilityseenfor
PSM and Glucantime (1). Unacceptable toxicity has
been reported with batches of some antimonials
made in India (2); these batches have been found to
have abnormally high osmolality. However, such
toxicity has not been reported with SSG made by
Albert David Ltd (Dr Shyam Sundar, personal
communication, 1999). IDA and other laboratories
— including the Drug Control Laboratory, Ministry
of Health, Khartoum, Sudan — have found SSG to
be of consistently high quality. IDA inspected the
production plant in India in 1997, and found it to
conform to Good Manufacturing Practices. MSF–H
therefore undertook a series of evaluations of PSM
versus SSGtoestablishwhetherthetwocompounds
weresimilarinefficacyandtolerabilityunderthefield
conditions where kala-azar is treated. This hospital-
based study is the first evaluation in this series.
Methods
Study site
Thestudy was carriedoutina kala-azar endemic area
of Kenya at the Ortum Mission Hospital in West
Pokot (catchment area population of 80000, con-
sisting mainly of the semi-nomadic Pokot tribe),
where approximately 100 kala-azar patients are
treated a year. The hospital has 109 beds, is staffed
by two doctors and two medical assistants, and has a
well-established nurse training school. There is a
laboratory with two trained technicians who are
competent in carrying out microscopy of splenic and
lymph-node aspirates. All kala-azar patients are
admitted as inpatients for their treatment. The
hospitalisfundedbyprivatedonationsandthedrugs
for the trial were donated by MSF–H. The hospital’s
policy is for patients to make a financial contribution
towards their care, and this policy was not altered
during our study.
Ethics
The study was carried out with strict observance of
theDeclarationofHelsinki(1997).Theprotocolwas
internally reviewed at MSF–H for ethical and




Makuch & Simon’s formula (3, 4) can be used to
calculate sample sizes for comparative studies if the
objective is to show that two treatments are equally
effective.Forthispurpose,thedifferenceinoutcome
thatwouldleadoneofthetreatmentstobediscarded
as inferior needs to be specified. For kala-azar
treatment we judged this to be a 20% difference in
cure rate. Since PSM has repeatedly been found to
have a cure rate of about 95% for kala-azar in Africa,
we considered that a 75% cure rate for generic
sodium stibogluconate would be clinically unaccep-
table. Taking a = 0.05 and b = 0.1, we required
25 patients per treatment group. We also tested a
second set of assumptions suitable for an unpaired
prospectivestudywithadichotomousoutcome(cure
versus failure). Assuming the drugs differ by 20% in
their cure rate, 95% in one group versus 75% in the
other (a= 0.05; b =0.2), we required 49 patientsper
treatment group.
Allocation of patients
From June 1997 until July 1998all consecutive
patients who were diagnosed for the first time as
havingkala-azaratthestudyhospitalwerereferredto
a clerk who assigned them alternately to one of the
two treatment groups, SSG or PSM. The clerk
operatedindependentlyofhospitalstaff,andwasnot
given any medical details of the patients. Patients
wereunawareofwhichgrouptheyhadbeenassigned
to until the treatment started. Those who did not
consenttobeinthestudyreceivedPSMinthenormal
manner. Trial patients were given a small incentive
(a free mosquito net and blanket) to attend the
follow-upat6months,buttherewasnoincentivefor
themtoparticipateinthestudy.Allpatients,whether
in the study or not, were charged for bed and board,
butthetrialpatientswhoreceivedeitherSSGorPSM
were not charged for the treatment, as is the usual
practice at the hospital.
Diagnosis and inclusion criteria
Clinical suspicion of kala-azar was defined according
to standard MSF–H guidelines: a history of fever
lasting 52 weeks (with exclusion of malaria), and
either splenomegaly or wasting. Kala-azar was
confirmed either by serology or by detection of
Leishmania amastigotes in Giemsa-stained splenic
aspirates. In addition, serology by the direct
agglutination test (DAT) was performed in the
MSF–H laboratory in Nairobi. Splenic aspirates were
read at the hospital and later confirmed by an
independent MSF–H microscopist. It may be noted
that patients were included even if they had severe
kala-azar, or comorbidity such as anaemia or
cachexia. Pregnancy, breastfeeding, advanced age
and infancy were not reasons for exclusion.
Exclusions
Patients with a past history of kala-azar or who had
received any antimonials in the past were excluded.
Patients who were clinically suffering from kala-azar
but had both a negative DAT test and a negative
splenic aspirate were also excluded.
Treatment
SSG was from batches 4P345, 5P169 and 5P233;
PSMwasfrombatchesA6629A,E6629A,D6629A,
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card was used to ensure that patients received either
PSM or SSG by intramuscular injection daily for
30 days. For both groups the dose was 20 mg of
pentavalent antimony (Sb
V) per kg body weight per
day; the minimum dose was 2 ml (200 mg Sb
V) with
no upper limit on the dose (5–7). Generic sodium
stibogluconate is supplied in vials of 30 ml, and
Pentostam
t in 100-ml vials; both preparations are
clear colourless solutions containing 100 mg Sb
V per
ml. Injections of more than 10 ml were given in two
aliquots, one in each buttock. Intercurrent illnesses
were treated in according to the hospital’s usual
protocols. Blood transfusions were available for
anaemic patients. Vitamin K was given to patients
who had a history of bleeding.
Response
Our main outcome measure was the initial cure rate.
We estimated that the relapse rate in antimonial-
treated patients who were initially cured was <10%,
and that the nomadic lifestyle of the patients would
make follow-up difficult. At discharge, the patients
were considered an initial cure if they had received
injectionsfor>28days,wereclinicallywell,andhada
negative splenic aspirate at the end of treatment. If
the spleen had completely regressed, the patient was
discharged without an aspirate at the clinician’s
discretion. Patients who had a positive splenic
aspirate at the end of treatment, or who were
clinically unwell continued to receive treatment until
two negative aspirates had been obtained, taken one
week apart. If at the follow-up visit, 6 months after
discharge, patients were clinically well, they were
considered a definitive cure. A further splenic aspirate
was performed only if the patient was unwell and the
clinician was suspicious of relapsed kala-azar.
Evaluations
The nurses were trained to reduce bias in recording
symptoms and treatment of intercurrent illness. At
enrolment,thefollowingdatawererecordedforeach
patient: name, age, sex, address, height (cm), weight
(kg), spleen size (in cm from the costal margin in the
anterioraxillarylinetothefurthestpointofthespleen
during quiet breathing), haemoglobin level (g/dl),
DAT result, and the number of months of illness.
During treatment, any medical complaints were
recorded in the patient’s notes daily. Specific
enquiries about possible side-effects and toxicity
werenotroutinelyaskedbythestafftoavoidpossible
bias. At discharge, the following parameters were
recorded:spleensize,haemoglobinlevel,weight,and
splenic aspirate result. At the 6-month follow-up, as
many as possible of the following parameters were
obtained from each patient (field visits restricted the
collection of some data): weight, spleen size,
haemoglobin level, whether the patient had a history
of fevers that were unresponsive to antimalarials, the
presence of post-kala-azar dermal leishmaniasis
(PKDL) or PKDL-associated iritis, and the clin-
ician’s impression of the patient (well and cured, or
unwellandrelapse).Asplenicaspiratewasperformed
if there was suspicion of relapse. Owing to the
distance and expense for the patients to attend
follow-up at the hospital, outreach trips to distant
villages were undertaken to locate the trial patients.
Because of their semi-nomadic lifestyle it was
difficult to trace many patients at the 6-month
follow-up; local chiefs were then interviewed to
obtain a verbal report on missing patients’ health.
Results
Atotalof102patientswereenrolledbetween10June
1996 and 30 July 1998, comprising all the patients
treatedinthehospitalforkala-azarduringthisperiod;
no other patients outside the study received the
treatment. Splenic aspirates to diagnose kala-azar
were taken from all 102 patients; 85 had a single
aspirate and 17 had repeated aspirates, the first
aspirate being negative for parasites despite strong
clinical suspicion. Two patients had repeatedly
negative splenic aspirates, and were diagnosed by a
stronglypositiveDATandclinicalfeatures:theywere
both in the SSG group, and responded to treatment.
For the 93 patients who received DAT testing,
85 werestronglypositive,5wereborderlinepositive,
and 3 were negative. All 8patients with borderline or
negative DAT results had positive splenic aspirates.
A total of 51 patients were allocated to receive SSG
and51toPSM.Therewerenosignificantdifferences
inthebaselinedemographiccharacteristicsordisease
severity between the two groups (Table 1).
Outcome
None of the outcome measures was significantly
different between the two treatment groups (see
Table 2). In the PSM group, 2 patients defaulted (on
days 27 and 30), and 3 died (on days 14 and 15, and
2 days after finishing treatment). In the SSG group,
2 patients defaulted (days 24, 30) and 1 died on day
10. There was no excessive vomiting, bleeding, or
the need for transfusion in either group. To diagnose
initial cure, we performed test-of-cure splenic
aspirates at the end of treatment for 80 patients —
44 in the SSG group (43 negative and one positive)
and 36 in the PSM group (all negative). The sole
patient with a positive end-of-treatment aspirate
received 15 further daily injections of SSG and had
two further negative aspirates. Follow-up at
6 months was achieved with 58patients; 30 were
in the SSG group — 16 were examined and
definitively cured, 9 were reported to be well by
the chief or a close relative, 4 had relapsed (proven
by splenic aspirate), and 1 had a clinical relapse (no
aspirate available). In the PSM group, 28patients
were followed up — 18were examined and
definitively cured, 9 were reported to be well, and
1 patient had aspirate-confirmed relapse. There were
no reports of PKDL.
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ResearchDiscussion
We found no important clinical differences between
the use of generic sodium stibogluconate and
Pentostam
t in Kenyan patients with kala-azar.
There are, however, certain shortcomings of this
study that should be noted. First, though the study
ranks among the larger prospective evaluations of
drugs for kala-azar (8), our sample size only
permitted detection of statistically significant differ-
ences of efficacy between the drugs of about 20%.
We are currently conducting larger studies in
Ethiopia and the Sudan to strengthen the conclu-
sions of the present study. Second, the allocation of
patients to treatment groups was alternate and not
random, and the hospital staff were not blinded to
the treatment given. However, the slides of splenic
aspirates were read ‘‘blind’’, and the main outcome
measures (death, initial cure, or definitive cure) are
unlikely to have been affected by a knowledge of
the treatment received.
Generic SSG and Pentostam
t should be
recognized as being the same drug. Like other
pentavalent antimonials, generic SSG is a mixture of
organometallic compounds (Mr = 100–4000) (9). All
fractions of the mixtures have similar in vitro anti-
leishmanial activity against amastigotes (10). The
lowerpriceofgenericSSGisamajoradvantageandit
is currently available from IDA for approximately
US$ 2.21 per 30-ml bottle, equivalent to US$ 10.60
per patient in our study (median body weight
= 24 kg, corresponding to a median of 144 ml of
Table 1. Baseline characteristics of kala-azar study patients treated
with generic sodium stibogluconate (SSG) and Pentostam
t (PSM)
Total SSG group PSM group P-value
a
(n = 102) (n = 51) (n = 51)
Mean age (years) 9 (2–40)
b 7 (2–40) 9.5 (2–28) 0.34
No. of patients aged 25/55/32 16/19/16 9/26/16 0.22*
45/<16/>16 years
Sex (M/F) 72/30 35/16 37/14 0.83**
Mean weight (kg) 23.6 20.8 (7.4–55) 24.4 (11–52) 0.37
(7.4–55)
Mean height (cm) 123 117 (37–182) 131 (49–184) 0.39
(37–184)
Mean spleen size (cm) 13.5 13 (5–23) 14.3 (6.7–20) 0.1
(5–23)
Mean haemoglobin 6.6 6.3 (3.8–10) 7 (3.6–10.8) 0.99
level (g/dl) (3.6–10.8)
DAT
c postive/borderline/ 85/5/3/9 42/4/3/2 43/1/0/7 0.19*
negative/not done
Splenic aspirate: 100/2 49/2 51/0 0.5**
Positive/negative
Mean duration of 3 (1–48) 3 (1–48) 3 (1–12) 0.6
illness (months)
a Mann–Whitney U-test, except * = w
2 test and ** = Fisher’s exact test.
b Figures in parentheses are the range.
c DAT = direct agglutination test for Leishmania antibodies.
Table 2. Events during and after treatment of kala-azar patients with generic sodium stibogluconate
(SSG) and Pentostam
t (PSM)
Total SSG group PSM group P-value
a Odds ratio
(n = 102) (n = 51) (n = 51)
Mean no. of injections received 30 (12–45)
b 30 (12–45) 30 (14–30) 0.7* –
No. of patients vomiting 12 7 5 0.8 1.46; 0.37–6.29
c
No. of patients with rash 27 14 13 >0.9 1.11; 0.42–2.94
No. of patients with jaundice 2 1 1 >0.9 1.0; 0.01–80.05
No. of patients transfused/ 43 / 60 23/32 20 / 28 0.7 1.27; 0.54–3.02
units of blood given
TOC
d negative/positive/not done 79/1/22 43/1/7 36/0/15 >0.9 –
No. initially cured 93 47 46 >0.9 1.27; 0.26–6.84
No. who died 4 1/ on day 10 3/on days 14, 15, 32 >0.9 0.32; 0.01–4.19
No. who defaulted 4 2/on days 24, 30 2/on days 27, 30 >0.9 –
No. followed up at or beyond 6 months 58 30 28 0.84 1.07; 0.43–2.67
Relapses at or beyond 6 months 6/58; 10%
e 5/30; 17%
e 1/28; 4%
e 0.19 5.4; 0.54–265
Definitively cured 52/58; 90%
e 25/30; 83%
e 27/28; 96%
e 0.19 0.19; 0.004–1.87
a Fisher’s exact test, except * = Mann-Whitney U-test.
b Figures in parentheses are the range.
c Figures in italics are the 95% confidence intervals.
d TOC = test-of-cure aspirate at the end of treatment.
e Proportion.
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t can be
bought from IDA for US$ 115.18per 100 ml bottle,
i.eUS$ 165.86perpatientinourstudy.Allbatchesof
generic sodium stibogluconate provided by IDA
undergo a second round of quality control at the
association, where the assessment includes the
proportion of trivalent and pentavalent antimony
and the osmolality (M. de Goeje, personal commu-
nication). Generic SSG has been used to treat
hundreds of thousands of cases of kala-azar in
Bangladesh and India, with cure rates of ca. 95%
having been reported in a very large series (11). The
availabilityofcheapergenericsodiumstibogluconate,
subject to rigid quality controls, now makes it
possible for the health authorities in endemic areas
to provide affordable treatment to many more
patients with kala-azar in Africa. n
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Re ´sume ´
Comparaison entre une spe ´cialite ´e tu ng e ´ne ´rique de stibogluconate de sodium pour
le traitement de la leishmaniose visce ´rale au Kenya
Objectif Comparer l’utilisation d’une spe ´cialite ´ et d’un
ge ´ne ´rique de stibogluconate de sodium pour le
traitement de la leishmaniose visce ´rale (kala-azar).
Me ´thodes Au total, 102 patients atteints de kala-azar
confirme ´ ont e ´te ´ traite ´s par le stibogluconate de sodium
(20 mg/kgparjourpendant30jours)dansunho ˆpitalde
mission de la re ´gion de West Pokot au Kenya. Le
stibogluconate de sodium e ´tait administre ´ soit sous
formedePentostam
t(PSM),soitsouslaformege ´ne ´rique
correspondante(SSG);lespatientse ´taientre ´partisa ` tour
de ro ˆle dans chacun des groupes de traitement
(51 patients par groupe).
Re ´sultats Aucune diffe ´rence significative n’a e ´te ´
observe ´e, que ce soit au niveau des donne ´es de ´mo-
graphiques de base, de la gravite ´ de la maladie ou des
faitssurvenusencoursdetraitement.Troisde ´ce `sonte ´te ´
enregistre ´s dans le groupe PSM et un dans le groupe
SSG, et deux patients de chaque groupe ont e ´te ´ perdus
de vue. Sur 80 ponctions de rate effectue ´es pour e ´valuer
la gue ´rison, une seule e ´tait positive pour Leishma-
nia spp. (chez un patient traite ´ par SSG). Un suivi re ´alise ´
au bout de 6 mois au minimum a montre ´ que 6 patients
sur58 avaientrechute ´ (5danslegroupeSSGet1dansle
groupe PSM). Aucun parame `tre relatif a ` l’issue du
traitementn’e ´taitsignificativementdiffe ´rentd’ungroupe
a ` l’autre.
Conclusion Lapossibilite ´ dedisposera ` moindrecou ˆtde
stibogluconate de sodium ge ´ne ´rique soumis a ` des
contro ˆles de qualite ´ rigoureux permet maintenant aux
autorite ´s sanitaires des re ´gions d’Afrique ou ` le kala-azar
est ende ´mique de fournir un traitement a ` un nombre
beaucoup plus grand de patients.
Resumen
Comparacio ´n de las formas gene ´rica y patentada de estibogluconato so ´dico como
tratamiento de la leishmaniasis visceral en Kenya
Objetivo Comparar el uso del estibogluconato so ´dico
gene ´rico y patentado como tratamiento de la leishma-
niasis visceral (kala-azar).
Me ´todo Un total de 102 pacientes con kala-azar
confirmado fueron tratados en un hospital de misio ´nen
la regio ´n de West Pokot (Kenya) con estibogluconato
so ´dico (20mg/kg/dı´adurante 30dı´as),bien enforma de
Pentostam
t (PSM) o bien como preparado gene ´rico
(EGS). De forma alternativa, se asigno ´ a 51 pacientes a
cada grupo de tratamiento.
Resultados No se observaron diferencias significativas
enlotocantealascaracterı´sticasdemogra ´ficasbasaleso
la gravedad de la enfermedad, ası´ como tampoco en lo
que respecta a los eventos registrados durante el
tratamiento. Hubo 3 defunciones en el grupo PSM y una
en el grupo EGS; en cada grupo hubo dos pacientes que
abandonaron el tratamiento. So ´lo uno de los 80 aspi-
rados esple ´nicos de confirmacio ´n de la curacio ´n fue
positivo para Leishmania spp., y se trataba de un
pacientedelgrupoEGS.Elseguimientorealizadoalcabo
de un periodo mı´nimo de seis meses mostro ´ que habı´an
recaı´do seis de 58 pacientes: cinco en el grupo tratado
con EGS y uno en el grupo tratado con PSM. No se
observarondiferenciassignificativasenningunavariable
de resultado final entre los dos grupos.
Conclusio ´nGracias a la disponibilidad de estibogluco-
nato so ´dico gene ´rico ma ´s barato, y siempre que se
aplique un control de calidad estricto, las autoridades
sanitarias de las zonas con kala-azar ende ´mico pueden
hoy suministrar tratamiento a muchos ma ´s pacientes en
A ´frica.
392 Bulletin of the World Health Organization, 2001, 79 (5)
ResearchReferences
1. Franco MA et al. Antimony oxidation states in antileishmanial
drugs.AmericanJournalof TropicalMedicine andHygiene, 1995,
52: 435–437.
2. Sundar S et al. A cluster of cases of severe cardiotoxicity among
kala-azar patients treated with a high-osmolarity lot of sodium
antimony gluconate. American Journal of Tropical Medicine
and Hygiene, 1998, 59: 139–143.
3. Makuch R, Simon R. Sample size requirements for evaluating
a conservative therapy. Cancer Treatment Reports, 1978,
62:1037–1040.
4. Pocock SJ. Clinical trials: a practical approach. London,
John Wiley & Sons, 1983.
5. Manual on visceral leishmaniasis control. Geneva, World Health
Organization, 1996 (unpublished document WHO/LEISH/96.40).
6. Berman JD. Human leishmaniasis: clinical, diagnostic, and
chemotherapeutic developments in the last 10 years. Clinical
Infectious Diseases, 1997, 24: 684–703.
7. Herwaldt BL, Berman JD. Recommendations for treating
leishmaniasiswithsodiumstibogluconate(Pentostam)andreview
ofpertinentclinicalstudies.AmericanJournalofTropicalMedicine
and Hygiene, 1992, 46: 296–306.
8. Seaman J et al. Epidemic visceral leishmaniasis in Sudan: a
randomizedtrialofaminosidineplussodiumstibogluconateversus
sodium stibogluconate alone. Journal of Infectious Diseases,
1993, 168: 715–720.
9. Berman JD, Grogl M. Leishmania mexicana: chemistry
and biochemistry of sodium stibogluconate (PentostamT).
Experimental Parasitology, 1988, 67: 96–103.
10. Roberts WL, Rainey PM. Antileishmanial activity of sodium
stibogluconate fractions. Antimicrobial Agents and Chemo-
therapy, 1993, 37: 1842–1846.
11. Chowdhury S et al. Positive response to sodium antimony
gluconate administration in visceral leishmaniasis seropositive
patients. American Journal of Tropical Medicine and Hygiene,
1991, 44: 390–393.
393 Bulletin of the World Health Organization, 2001, 79 (5)
Comparison of two treatments for visceral leishmaniasis in Kenya